Tocagen Announces Change to Virtual Format for Special Meeting of Stockholders PR Newswire SAN DIEGO, May 28, 2020 SAN DIEGO, May 28, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA...
Tocagen Reports First Quarter 2020 Financial Results PR Newswire SAN DIEGO, April 23, 2020 SAN DIEGO, April 23, 2020 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), historically a clinical-stage...
Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results Definitive merger agreement with Forte Biosciences announced February 19, 2020 PR Newswire SAN DIEGO, Feb. 27, 2020 SAN DIEGO...
Tocagen and Forte Biosciences Announce Merger Transaction to Create Nasdaq-listed Company Focused on Advancing Forte's Late-Stage Clinical Program for Atopic Dermatitis $14 Million to be Invested...
Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual Meeting PR Newswire SAN DIEGO, Nov. 22, 2019 SAN DIEGO, Nov. 22, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA...
Tocagen Reports Third Quarter 2019 Financial Results and Business Updates PR Newswire SAN DIEGO, Nov. 12, 2019 SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a...
Tocagen Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer Annual Meeting Phase 3 Toca 5 trial data and details on planned trial in newly diagnosed glioblastoma to be...
Tocagen to Report Third Quarter 2019 Financial Results and Business Updates on Tuesday, November 12 PR Newswire SAN DIEGO, Nov. 6, 2019 SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Tocagen Inc...
Tocagen Announces Restructuring to Focus on Clinical Development Toca 5 full results to be presented at the upcoming Society for Neuro-Oncology Annual Meeting PR Newswire SAN DIEGO, Oct. 3, 2019...
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer Management to host conference call today at 8:30 a.m. Eastern PR Newswire SAN DIEGO, Sept. 12, 2019 SAN DIEGO, Sept. 12...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.